Bio-Techne Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne or view top-rated stocks.

Wall Street analysts have given Bio-Techne a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bio-Techne is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bio-Techne.

Bio-Techne will be holding an earnings conference call on Thursday, August 5th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "3330876".

Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported $1.79 EPS for the quarter, topping the Zacks' consensus estimate of $1.24 by $0.55. The biotechnology company earned $243.55 million during the quarter, compared to analyst estimates of $228.57 million. Bio-Techne had a net margin of 21.74% and a trailing twelve-month return on equity of 13.37%. The business's revenue was up 25.1% on a year-over-year basis. During the same period last year, the company earned $1.39 EPS.
View Bio-Techne's earnings history.

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TECH stock has increased by 167.5% and is now trading at $483.11.
View which stocks have been most impacted by COVID-19.

Bio-Techne declared a quarterly dividend on Thursday, May 6th. Stockholders of record on Monday, May 17th will be given a dividend of $0.32 per share on Friday, May 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Friday, May 14th.
View Bio-Techne's dividend history.

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.27%. Bio-Techne does not yet have a strong track record of dividend growth. The dividend payout ratio of Bio-Techne is 33.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 18.99% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

11 analysts have issued 1 year price objectives for Bio-Techne's shares. Their forecasts range from $340.00 to $490.00. On average, they anticipate Bio-Techne's stock price to reach $421.50 in the next year. This suggests that the stock has a possible downside of 12.8%.
View analysts' price targets for Bio-Techne or view top-rated stocks among Wall Street analysts.

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

Some companies that are related to Bio-Techne include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of TECH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by many different retail and institutional investors. Top institutional investors include Obermeyer Wood Investment Counsel Lllp (0.25%), State of Alaska Department of Revenue (0.06%), Oregon Public Employees Retirement Fund (0.05%), New Mexico Educational Retirement Board (0.02%), Affiance Financial LLC (0.02%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne.

TECH stock was sold by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Raymond James Trust N.A., and Affiance Financial LLC. Company insiders that have sold Bio-Techne company stock in the last year include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, and Kim Kelderman.
View insider buying and selling activity for Bio-Techne or view top insider-selling stocks.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, IFM Investors Pty Ltd, Obermeyer Wood Investment Counsel Lllp, New Mexico Educational Retirement Board, State of Alaska Department of Revenue, and Bruderman Asset Management LLC. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne or or view top insider-buying stocks.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $483.11.

Bio-Techne has a market capitalization of $18.79 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis.

Bio-Techne employs 2,300 workers across the globe.

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., CLINIQA Corporation, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

Bio-Techne was founded in 1981.

The official website for Bio-Techne is www.bio-techne.com.

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at (612) 379-2956 or via email at [email protected]